Investigative Group

Top DOJ Official Reportedly Helped Keep Opioid Executives From Prison. She’s Since Defended Pharma Against The Government

U.S._Department_of_Justice_headquarters | Circa August 2006 | CC BY-SA 3.0, https://commons.wikimedia.org/w/index

As part of the plea deal, Purdue and three executives conceded they downplayed OxyContin’s addictiveness and collectively paid a historic $635 million in fines in 2007. No one saw jail time.

Meanwhile, more than 200,000 people have died from overdoses involving prescription opioids since OxyContin was launched in 1996, according to the Centers for Disease Control and Prevention.

Purdue is privately owned by the Sackler family, whose wealth skyrocketed after OxyContin sales raked in $35 billion over a 20-year period, giving the family a $13 billion net worth and making them the 19th richest in the U.S. in 2016, according to Forbes.

Massachusetts was one of the states to file a lawsuit against Purdue in 2018, but it uniquely named eight members of the Sackler family. A recent complaint cites documents indicating the Sacklers headed a campaign to deceive doctors about the dangers of OxyContin and passed blame of negative press onto addicts.

“The launch of OxyContin tablets will be followed by a blizzard of prescriptions that will bury the competition,” Richard Sackler, the son of a Purdue founder and the company’s president from 1999 to 2003, said while celebrating the drug’s entrance to the market, according to a document cited in the complaint. “The prescription blizzard will be so deep, dense, and white.”

Bush’s Justice Department Rejected Felony Charges After A Four-Year Investigation

Then-U.S. Attorney John Brownlee concluded a four-year investigation and recommended indicting the three Purdue executives on felony charges, including conspiracy to defraud the government, in September 2006, the Times reported in May 2018.

But top DOJ officials didn’t support his recommendation after meeting with Purdue executives and their defense team, according to Times reporter Barry Meier.

One defense lawyer for Purdue was Mary Jo White, a former federal prosecutor, and an adviser to the company’s legal team was former New York Mayor Rudy Giuliani, who was also once a U.S. attorney.

The head of DOJ’s criminal division at the time, Alice Fisher, was one of the officials who didn’t support Brownlee’s recommendation, according to the Times. She’s now a partner at the law firm Latham & Watkins.

Her bio page says she recently represented “[g]lobal pharmaceutical companies in [Securities and Exchange Commission] and DOJ [Foreign Corrupt Practices Act] investigations resulting in settlement resolutions and declinations of prosecutions.”

It also says she represented “Several global manufacturing companies about maintaining FCPA compliance and obtaining two declinations of prosecution.”

Fisher did not respond to multiple requests for comment.

Brownlee publicly supported the decision not to prosecute the Purdue executives, but, according to Meier, he was privately upset. Brownlee did not respond to The Daily Caller News Foundation’s request for comment, and he’s previously declined to comment to other publications.

Top DOJ Officials Questioned Purdue Probes After Hearing From Company Representatives

There were additional occasions when top DOJ officials scrutinized Brownlee’s investigation after Purdue representatives contacted them.

After speaking with the company’s defense attorneys in 2005, then-Deputy Attorney General James Comey asked Brownlee why he was pursing Purdue, Brownlee said during a 2007 congressional hearing. Brownlee, who was the federal prosecutor for the western district of Virginia, drove to Washington to explain the situation to Comey, who ultimately gave Brownlee the go-ahead to continue.

Additionally, Brownlee’s name appeared on a list of U.S. prosecutors recommended for termination soon after he ignored a top DOJ aide’s request to delay the plea deal.

Hours before the plea deal was set to expire in October 2006, Deputy Attorney General Paul McNulty’s chief of staff, Michael Elston, called Brownlee and asked him to extend Purdue’s deadline, the U.S. attorney testified.

“He told me he received a phone call from the defense lawyers about the case and that that the counsel had once again said that we were moving too quickly, that we had needed more time,” Brownlee said.

“Through his questions of me, I sensed that he was inquiring almost on their behalf,” he continued, noting Elston said he wasn’t calling at McNulty’s request.

Elston’s lawyer later said McNulty, who had replaced Comey, had asked Elston to call Brownlee, according to The Washington Post.

Elston told TheDCNF on Friday he called Brownlee on behalf of McNulty after the deputy attorney general noticed the deadline for the plea agreement was unusually tight. Elston said he was asking the prosecutor for information and not to tell Brownlee to give Purdue more time.

McNulty did not respond to a request for comment.

Regardless, Brownlee stuck with the original deadline and Purdue agreed to it hours later, Brownlee testified.

Eight days later, Brownlee’s name was included on a list Elston compiled of prosecutors recommended for termination, though he ultimately was not fired, the Post reported in 2007.

Elston told TheDCNF he did not recall any connection between Brownlee being included on the list and the Purdue case.

Also during the course of the government’s investigation into Purdue, Giuliani met with Asa Hutchinson in 2005, who was then the Drug Enforcement Administration’s chief, Vanity Fair reported in 2007. The meeting came after the DEA found OxyContin could be responsible for 464 deaths over a two-year period.

Following his meeting with Giuliani, Hutchinson began asking DEA officials why they were still looking into Purdue.

Hutchinson is now the governor of Arkansas. He did not return a request for comment.

Legal Battles Against Purdue And The Sacklers Intensify

Deaths related to opioids have skyrocketed since the 2007 plea agreement, and the Sackler family, Purdue’s owners, largely kept its name separate from the epidemic, until recently.

TheDCNF began its “American Cartel” series in 2017, which tied the Sackler name to Purdue and investigated the family’s charitable givings. The Sacklers, until then, were known for their philanthropy, with famous institutions like New York’s Metropolitan Museum of Art naming entire sections after the family.

Meanwhile, lawsuits against Purdue from across the country have racked up. Evidence has trickled out showing the Sacklers knew about OxyContin’s dangers earlier than they said and showing they kept that information from the public.

Federal prosecutors discovered that Purdue Pharma knew OxyContin was being abused soon after the drug’s 1996 launch, a confidential DOJ report shows, the Times reported in May 2018. The report also found members of the Sackler family were aware that OxyContin and its morphine-based predecessor were being abused.

And a Tuesday court filing alleged that the Sacklers knew that Purdue knew OxyContin was being illegally dealt and abused, but failed to report it to authorities.

“This is not too bad,” Richard Sackler said in 2001 while serving as Purdue’s president and after a federal prosecutor reported that there were 59 deaths involving OxyContin in just one state, according to a document cited in the complaint. “It could have been far worse.”

Purdue, at the direction of the Sacklers, pushed for doctors to prescribe higher doses of OxyContin and for longer periods, resulting in massive profits for the company and the family, the lawsuit claims.

The Massachusetts complaint “irresponsibly and counterproductively casts every prescription of OxyContin as dangerous and illegitimate,” Purdue spokesman Bob Josephson said in a statement, calling the allegations “sensational” and “misleading.”

He accused the state of trying to “vilify” the company.

Josephson did not comment on Purdue’s communications with the DOJ.

He also said the Food and Drug Administration has ruled OxyContin continues to be “safe and effective for their intended use” and that the government determined in 2013 Purdue had fulfilled its obligations related to the marketing of its medications.

“The complaint is littered with biased and inaccurate characterizations,” Josephson said.

The only known instance where a Sackler was deposed was sealed as part of a $24 million settlement with Kentucky in December 2015.

Purdue recently lost an appeal to keep Richard Sackler’s deposition secret, but the company is continuing to contest the ruling. The testimony remains sealed while legal battles persist.

Follow Ethan on Twitter. Send tips to [email protected].